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followed by the proliferation of
fibroblasts and vascular endothelial
cells at the injured site, leading to
the formation of granulation
tissue.5 The presence of chronic
inflammation, granulation tissue,
and deformation of the bronchial
tree as well as atrophic, hyper-
plastic, and dystrophic changes in
the ciliated epithelia promotes epi-
thelization of the FB and impairs
bronchial patency.
Our patient presented with
pulmonary infection associated
with bronchial obstruction. The
infection was refractory to tradi-
tional treatment due to an endo-
bronchial obstruction. Upper air-
way extraction was not possible, as
the patient had a continued need
for mechanical ventilation, and
there was a risk of injuring the
vocal cords and other upper air-
way structures. The factors that
influenced the use of flexible
bronchoscope over rigid broncho-
scope were the center’s
expertise, smaller size and better
navigational properties. Flexible
bronchoscope permitted the
examination of the lower airways
with less risk of trauma. An
accessory extraction pathway in
the form of a tracheostomy was
utilized to remove the FB, avoid-
ing further damage. This case
illustrates a pathogenic chronic
endobronchial FB, its dissection,
and a complex extraction proce-
dure which included a tracheal
opening for removal. After a
detailed review of the available lit-
erature (Cochrane, EBSCOhost,
and PubMed), most of the pre-
vious publications involved pedia-
tric patients and acute aspiration of
FBs. Debeljak et al6 published 62
cases of bronchoscopic removal of
FBs in adults in a period of
24 years, only one was associated
with tracheostomy and was not
simultaneously performed. The
successful outcome and complete
resolution of the patient’s illness
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Cryoablation of the pulmo-
nary veins has become a favorable
treatment option for symptomatic
atrial fibrillation refractory to
conservative treatment with anti-
arrhythmic drugs.1 Although it is
generally considered a safe proce-
dure, necrotic lesions of anatomi-
cally adjacent structures (eg,
esophagus, phrenic nerve, vagal
nerve, bronchi, and lungs) have
FIGURE 4. Foreign body after extraction submerged in formalin.
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been reported, including a few
cases of hemoptysis.2–5 To the best
of our knowledge, we here present
the first report on serial broncho-
scopic follow-up of a cryoa-
blation-induced lesion to the left
main bronchus with successive
healing of the lesion under con-
servative treatment.
CASE REPORT
A 44-year-old female patient presented
with increasing dyspnea and minor
hemoptysis for 4 days. Three days
before the onset of her symptoms, she
underwent cryoablation of the pulmo-
nary veins due to symptomatic parox-
ysmal atrial fibrillation resistant to
antiarrhythmic drugs. Each pulmo-
nary vein had been ablated for 240ms
with minimal temperatures of −47 to
−49°C (Artic Front ablation balloon
28mm; Medtronic) under anticoagu-
lation therapy with heparin (2 intra-
venous single shots of 5000 and 4000
Units, respectively). The immediate
postinterventional course was unevent-
ful without any clinically apparent
bleeding complications. To prevent
scar tissue–induced thromboembolism
in the left atrium therapeutic oral
anticoagulation with rivaroxaban was
introduced per standard protocol.6
By the time of presentation at our
emergency room, the patient was
hemodynamically stable with normal
oxygen saturation on ambient air. All
laboratory values (blood count, crea-
tinine, urea, and C-reactive protein)
were within normal range. The initial
computed tomographic scan with
angiography excluded any severe
active arterial bleeding and showed
only discrete ground glass opacity
in the area of the right inferior
pulmonary vein. Transthoracic echo-
cardiography revealed no structural
abnormalities with normal left and
right heart function. We admitted the
patient to our ward, administered
500mg tranexamic acid orally, and
stopped oral anticoagulation with
rivaroxaban. A flexible video bron-
choscopy revealed a necrotic lesion of
~0.5×1 cm in the distal left main
bronchus, adjacent to the left superior
pulmonary vein (LSPV) (Fig. 1).
Using endobronchial ultrasound, we
identified the LSPV lying underneath
the necrotic lesion; the distance to
the bronchial wall was 3.3mm. We
administered an antitussive medi-
cation with codein and dextromethor-
phan as well as antibiotic therapy with
amoxicillin/clavulanate to prevent a
rupture of the necrotic lesion into the
left atriumwith fatal consequences. To
prevent the formation of thrombotic
material in the left atrium after the
cryoablation, unfractionned heparin in
low therapeutical doses (targeted
antifactor X activity of 0.3 to 0.4 IU/
mL) was started.
The patient remained under
observation on our regular ward and
we performed a bronchoscopic follow-
up at day 4, which revealed a stable
situation of the necrotic lesion without
signs of active bleeding or progression
of the necrotic area. She was dis-
charged after 7 days, and the anti-
coagulation was changed to dabiga-
tran because of the availability of a
rapid reversibility using the specific
antidote (Idarucizumab). We per-
formed serial bronchoscopic follow-up
examinations at days 12, 22, 28,
2 months, and 3 months (Fig. 2). The
necrotic area initially showed a
demarcation of the boarders, and
thereafter a gradual shrinking, finally
resulting in the formation of scar tis-
sue. At 2 months, fibrinous material
attached to the healing ulcer was
observed during a clinical diagnosed
viral infection of the upper respiratory
tract. The viral and microbiological
endotracheal sampling returned neg-
ative. At 3 months the ulcer was
completely healed. The patient stayed
asymptomatic. The oral anticoagu-
lation was later changed to Edoxaban
due to a presumed adverse drug
reaction to dabigatran (dizziness and
headache), which resolved afterwards.
DISCUSSION
There are a few cases of hemopt-
ysis after cryoablation of the
pulmonary veins reported in the
literature. In 2 reports, broncho-
scopy showed similar lesions in
the left main bronchus close to the
left upper pulmonary vein.4 We
can explain this similar localiza-
tion because of the anatomic
proximity of the LSPV and the
left main bronchus (Fig. 1). In a
single center retrospective analysis,
Kumar et al3 reported 6 of
283 patients (2.1%) with minor
hemoptysis, appearing at day 0 to
day 5 and resolving spontaneously
with or without discontinuation of
FIGURE 1. Computed tomographic thorax angiography, demonstrating the
anatomic correlation of the distal left main bronchus and the left superior
pulmonary vein (arrow).
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anticoagulation; only 2 patients
had visible lesions in the bron-
choscopy. Furthermore, there are
2 reports of massive hemoptysis
after cryoablation, one requiring
immediate surgical intervention
because of an atriobronchial fis-
tula with fatal outcome.7 The
second case, a bleeding ulcer,
required massive blood trans-
fusion and reversal of the
anticoagulation.8
The pathophysiological mech-
anism of the ulcer formation is
considered to be a thermal injury
of the bronchial walls during the
cryoablation. Verma et al9 per-
formed live bronchoscopy during a
cryoablation in 10 patients and
visualized ice formation in 59% of
the freezes only in the left main
bronchus during cryoablation in
the left upper pulmonary vein; in
contrast, in the right bronchus no
ice formation was observed during
cryoablation of the right upper
pulmonary vein. The minimal
temperature achieved, the duration
of cryoablation and a deeper
positioning of the balloon in
the pulmonary vein have been
reported as risk factors for bron-
chial necrosis.3 In our case, the
minimal temperature (−47 to
−49°C) was within the targeted
range. An alternative cause of
hemoptysis after cryoablation is
the development of a pulmonary
vein stenosis, causing lung
circulatory stagnation and pulmo-
nary infiltrates causing diffuse
parenchymatous bleeding5 or
leading
to pulmonary artery dysfunction
with hypertrophy of the bronchial
arteries (occurring a few months
after the cryoablation10).
In our case, we provide the
first serial endoscopic follow-up
documentation of a bronchial
necrosis, guided by the 3 phases
of scar tissue formation (inflam-
mation, proliferation, and
remodeling) with a special inter-
est for the proliferative phase
where the risk of rupture is the
highest. Over 3 months we were
able to demonstrate a sponta-
neous healing of the necrotic area
with conservative therapy.
CONCLUSIONS
Localized bronchial necrosis caus-
ing hemoptysis is a rare event after
cryoablation of the pulmonary
veins for treatment of atrial fibril-
lation. As fatal outcomes have
been published due to venobron-
chial fistulas as well as rupture,
patients as well as health care
providers need to be sensitized to
this complication, which needs to
be investigated with immediate
chest computed tomographic scan
and bronchoscopy. Temporary
discontinuation or reduction of
the anticoagulation therapy should
be considered. We recommend
follow-up bronchoscopies to docu-
ment the healing of the necrotic
area and to anticipate emerging
complications, such as secondary
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FIGURE 2. Bronchoscopic follow-up at day 1, day 28, and after 3 months.
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We report a case of a 41-year-
old man who developed a delayed,
recurrent bilious pleural effusion
(cholethorax) following open hep-
atectomy and cholecystectomy.
CASE REPORT
A 41-year-old man presented to the
emergency department with right-sided
back pain. A computed tomography
(CT) scan of the abdomen was
unremarkable. He was discharged
home; however, returned a few days
later with intractable back pain and
dyspnea with diminished breath
sounds over the right lung field. A
chest CT with intravenous (IV)
contrast showed a new right-sided
pleural effusion. He was admitted
and a bedside thoracentesis showed
dark green fluid. Five-hundred seventy
milliliters of fluid was removed and
analysis determined it to be an exudate
(pleural fluid showed: lactate dehydro-
genase was 2214U/L, total protein
3.2 g/dL, glucose 114mg/dL, white
blood cell count 18060 with 97%
neutrophils) with negative cultures.
Bilirubin was not sent. His chest pain
improved and he was discharged home
with outpatient oncology follow-up to
await cytology results, which later
returned negative. He developed dysp-
nea and received an outpatient thor-
acentesis 3 weeks later with 1200mL
of yellow fluid removed. His dyspnea
again improved. Pleural studies were
similar to initial findings and cytology
was negative. Lacking a unifying
diagnosis, he was referred to interven-
tional pulmonary (IP) for evaluation.
In IP clinic, he appeared healthy,
and complained of dyspnea on exer-
tion. His medical history was sig-
nificant for rectal cancer metastatic to
the liver that was diagnosed
20 months prior. He had received
neoadjuvant chemotherapy with leu-
covorin, fluorouracil, and oxaliplatin
(FOLFOX) followed by concurrent
chemoradiation with capecitabine. Six
months after initiating chemotherapy,
he achieved partial response in pri-
mary and metastatic lesions, and
underwent abdominoperineal resec-
tion with end descending colostomy
and 4 separate liver wedge resections
followed by ultrasound-guided micro-
wave ablation of remaining lesions.
This was followed by adjuvant che-
motherapy with FOLFOX to com-
plete 8 cycles; however, he had recur-
rence in the liver (Fig. 1) and was
started on treatment with leucovorin,
fluorouracil, and irinotecan (FOL-
FIRI) along with bevacizumab. Nine
months after the initial surgery, he
underwent right hepatectomy, seg-
mental liver resection, and chol-
ecystectomy. A 10.3×6.8×12.1 cm
simple fluid collection was noted on
imaging following this procedure. This
fluid collection was again noted on
presentation to the emergency depart-
ment. It was stable in size and attrib-
uted to postoperative seroma.
Given this history, the suspicion
for cholethorax or malignant effusion
was high and repeat thoracentesis with
positron emission tomography-com-
puted tomography was recommended.
A total of 2000 mL was extracted
with guidance of pleural manometry
(Fig. 2). The pleural elastance was
5 cm H2O/L, consistent with free-
flowing fluid. The total bilirubin con-
tent of the fluid was 3.4mg/dL (serum
bilirubin 0.5mg/dL), which was con-
sistent with a cholethorax. positron
emission tomography-computed tom-
ography did not show fluorodeox-
yglucose avidity in the parietal pleura.
Given the elevated bilirubin, an mag-
netic resonance imaging (MRI) of the
abdomen with IV gadoxetate diso-
dium (Eovist) was performed which
showed a 4.0×7.4 cm fluid collection
between the resection margin and the
right hemidiaphragm with rapid
accumulation of Eovist, consistent
with biloma. Eovist is a hepatobiliary
specific agent that is taken up by
organic anion transporter proteins on
hepatocytes (same transporter protein
for bilirubin) and undergoes ∼50%
excretion through the biliary route,
providing delayed hepatic and biliary
tree imaging.1 The MRI also showed
potential extravasation into the pleural
space (Fig. 3).
After consultation with interven-
tional gastroenterology and radiology,
a percutaneous drainage catheter
(Argon Skater Medical, Frisco, TX)
was placed into the biloma. An endo-
scopic retrograde cholangiopan-
creatography with cholangiogram was
performed and showed a bile leak
from the right posterior intrahepatic
duct. A10Fr×9 cm Sof-Flex plastic
stent (Cook Medical, Bloomington,
IN) was placed in the common bile
duct. Concurrently, a 14Fr chest tube
(Teleflex Medical, Research Triangle
Park, NC) was inserted to remove the
rest of the right-sided pleural effusion
(∼2200mL) and immediately
removed after ultrasound confirm-
ation of complete fluid evacuation.
The effusion was negative for malig-
nancy. Following this procedure, the
biloma drain output and color
improved, along with his pulmonary
symptoms. A few weeks later, he
presented with fever and chills
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